Jeffrey J. Swigris, DO, MS; Kevin K. Brown, MD; Amanda Belkin, MPH
Potential Conflicts of Interest: Dr. Swigris: Grant (money to institution): NIH; Consultancy: Genentech; Grants/grants pending (money to institution): NIH; Payment for development of educational presentations: Intermune. Dr. Brown: Grant (money to institution): NIH; Consultancy: Genzyme, Gilead, Genentech, Fibrogen, Celgene, Amgen, Centocor, Novartis, Array Biopharma, Stromedix/Biogen, Ikaria, Pfizer, Mesoblast, Ironwood Pharma, Actelion, Almirall, Boehringer Ingelheim, Human Genome Sciences, Promedior, Phillips-Respironics, Medimmune; Grants/grants pending (money to institution): NIH; Other: unpaid board member of the Pulmonary Fibrosis Foundation; unpaid consultant for GeNO, GlaxoSmithKline, and MondoBiotech. Ms. Belkin: None disclosed.
Swigris JJ, Brown KK, Belkin A. Thalidomide for the Treatment of Cough in Idiopathic Pulmonary Fibrosis. Ann Intern Med. 2013;158:498. doi: https://doi.org/10.7326/0003-4819-158-6-201303190-00015
Download citation file:
Published: Ann Intern Med. 2013;158(6):498.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use